Thursday 18th March |
||
Time CET |
TRACK 1 | TRACK 2 |
13:00 – 13:10 | Welcome Prof. Sinthia Bosnic-Anticevich (Australia) |
|
13:10 – 14:40 |
COVID-19 session Chair: Prof. Antonio Anzueto (United States) COVID & Chronic Respiratory Disease: Risks and management COVID-19 and the future (what we need to do, with and without a vaccine) |
|
14:40 – 15:00 | Break |
|
15:00 – 16:30 |
Environment and Lung Health Chair: Prof. Joan B. Soriano (Spain) Impact of Global warming and Climate Change Inhalers and F-gas Pro/ Con: E-cigarette: is this a valuable aid to smoking cessation? |
Current questions in asthma management
Supported by Chair:Prof. Alberto Papi (Italy) & Prof. Giorgio Walter Canonica (Italy) New biologics in severe asthma - how to choose? Pro/ Con: Should SABAs be replaced as the reliever of choice? |
Friday 19th March | ||
13:00 – 14:30 |
COPD: Treatment controversies Chair: Dr. Marc Miravitlles (Spain) Pro/ Con: LABA/LAMA, should we start earlier? Pro: Dr. Bartolome Celli (United States) Con: Prof. Antonio Anzueto (United States) Pro/ Con: Triple therapy, does it reduce mortality? Pro: Dr. MeiLan Han (United States) Con: Dr. Anthony D'urzo (Canada) |
Child health – pediatric asthma Chair: Prof. Steve Turner (United Kingdom) & Prof. Nikos Papadopoulos (Greece) Pediatric asthma management during COVID – what changes? Asthma biomarkers in children Adults versus children: Differences between asthma guidelines and advice |
14:30 – 14:45 | Break |
|
14:45 – 16:15 |
ISAR Session: Severe asthma in real-life - learnings from ISAR and beyond Chair: Prof. David Price (United Kingdom) Overview of ISAR recent publications Ongoing research on Biolocs from ISAR The role of exacerbations on lung function trajectory and early intervention with Biologics Differences in asthma disease severity by socioeconomic status and ethnicity Approaches to identify hidden severe asthma within the COPD population - Panel discussion The future of registry: embedding data collection in routine care - Panel discussion |
ILD/IPF Session
Supported by Chair: Dr. Mark Jones (United Kingdom) Early identification of IPF - what new tools can help?
Post-COVID fibrosis |
Saturday 20th March | ||
13:00 – 14:30 |
Digital Health Chair: Prof. Henry Chrystyn (United Kingdom) The evidence for digital inhalers HE aspects of digital technologies |
|
14:30 – 14:45 | Break | |
14:45 – 15:45 |
Thresholds for referral Chair: Prof. Mike Thomas (United Kingdom) Wheeze/Asthm Allergy COPD |
|
15:45-16:00 | Closing remarks Prof. Sinthia Bosnic-Anticevich (Australia) |